Q3 FY2026
Filed Oct 27, 2026Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Q3 revenue increased 11% as reported and 12.5% organic, adjusted operating income and adjusted EPS increased, and the Company raised FY 2026 revenue guidance. GAAP results were affected by a $41,242 intangible asset impairment charge, resulting in a Q3 GAAP net loss of $ (38,432) and GAAP diluted loss per share of $ (0.68).
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Q3 2026 total revenueGAAP | $209.3M | – | 11 % |
| Q3 2026 product revenueGAAP | $209.3M | – | – |
| Q3 2026 royalty and other revenueGAAP | 44 | – | – |
| Q3 2026 organic revenue growthnon-GAAP | 12 % | – | – |
| Q3 2026 GAAP gross marginGAAP | 53.0% | – | – |
| Q3 2026 adjusted gross marginnon-GAAP | 53.0% | – | – |
| Q3 2026 loss from operationsGAAP | −$29.55M | – | – |
| Q3 2026 GAAP operating (loss) EBIT marginGAAP | (14.1) % | – | – |
| Q3 2026 adjusted income from operationsnon-GAAP | $33.29M | – | – |
| Q3 2026 adjusted operating (EBIT) marginnon-GAAP | 15.9 % | – | – |
| Q3 2026 net (loss) incomeGAAP | −$38.43M | – | – |
| Q3 2026 GAAP net (loss) income marginGAAP | (18.4) % | – | – |
| Q3 2026 adjusted net incomenon-GAAP | $29.88M | – | – |
| Q3 2026 adjusted net income marginnon-GAAP | 14.3 % | – | – |
| Q3 2026 diluted (loss) EPSGAAP | $ (0.68) | – | – |
| Q3 2026 adjusted EPS - dilutednon-GAAP | $ 0.53 | – | – |
| Q3 2026 adjusted EBITDAnon-GAAP | $43.84M | – | – |
| Q3 2026 adjusted EBITDA marginnon-GAAP | 20.9 % | – | – |
| Nine months ended September 30, 2026 total revenueGAAP | $607.7M | – | 13 % |
| Nine months ended September 30, 2026 product revenueGAAP | $607.6M | – | – |
| Nine months ended September 30, 2026 royalty and other revenueGAAP | 131 | – | – |
| Nine months ended September 30, 2026 organic revenue growthnon-GAAP | 12 % | – | – |
| Nine months ended September 30, 2026 GAAP gross marginGAAP | 54.2% | – | – |
| Nine months ended September 30, 2026 adjusted gross marginnon-GAAP | 54.1% | – | – |
| Nine months ended September 30, 2026 income from operationsGAAP | $ 370 | – | – |
| Nine months ended September 30, 2026 adjusted income from operationsnon-GAAP | $97.20M | – | – |
| Nine months ended September 30, 2026 net (loss) incomeGAAP | −$25.09M | – | – |
| Nine months ended September 30, 2026 adjusted net incomenon-GAAP | $87.81M | – | – |
| Nine months ended September 30, 2026 diluted (loss) EPSGAAP | $ (0.44) | – | – |
| Nine months ended September 30, 2026 adjusted EPS - dilutednon-GAAP | $ 1.55 | – | – |
| Nine months ended September 30, 2026 adjusted EBITDAnon-GAAP | $127.6M | – | – |
| Nine months ended September 30, 2026 adjusted EBITDA marginnon-GAAP | 21.0 % | – | – |
| Nine months ended September 30, 2026 cash provided by operating activitiesGAAP | 104,160 | – | – |
| Nine months ended September 30, 2026 purchases of property, plant and equipmentGAAP | (14,992) | – | – |
| Cash and cash equivalents at September 30, 2026GAAP | $727.0M | – | – |
| Marketable securities at September 30, 2026GAAP | 136,019 | – | – |
| Convertible Senior Notes due 2028, net at September 30, 2026GAAP | 555,596 | – | – |
FY 2026 outlook
- Revenue$844M - $852M
- Gross margin53.7% - 54.2%
- Tax rate~22%
- NoteAdjusted (non-GAAP) reported growth: 14.5% - 15.5%
- NoteAdjusted (non-GAAP) organic growth: 12% - 13%
- NoteAdjusted (non-GAAP) income from operations: $135M - $139M
- NoteAdjusted (non-GAAP) operating margin: 16.0% - 16.3%
- NoteAdjusted (non-GAAP) other income (expense): ~$18M
- NoteAdjusted (non-GAAP) EBITDA margin: ~21%
- NoteAdjusted (non-GAAP) net income: $119M - $122M
- NoteAdjusted (non-GAAP) earnings per share - diluted: $2.05 - $2.09
- NoteTotal reported revenue guidance reflects a neutral impact from foreign currency and an approximately 2.5 point tailwind from inorganic growth primarily from the BioLife acquisition net of the divestiture of Polymem.
What drove it
- Q3 reported revenue increased 11% and organic revenue growth was 12.5%.
- Management cited continued strength across its diversified portfolio, healthy trends in consumables and services, and a growing capital equipment order book.
- The BioLife acquisition closed on October 6, 2026 and is included in FY 2026 guidance from the closing date.
- Adjusted operating (EBIT) margin was 15.9 %, compared with 14.2 % in Q3 2025.
- Q3 adjusted EBITDA margin was 20.9 %, compared with 19.0 % in Q3 2025.
Concerns
- Q3 GAAP loss from operations was $ (29,546), compared to income from operations of $ 16,825.
- Q3 net loss was $ (38,432), compared to net income of $ 14,911.
- Q3 intangible asset impairment charges were 41,242, compared to —.
- The Company cited risks related to successful BioLife integration and realizing expected acquisition benefits and synergies.
- The Company cited risks that demand for its products could decline and that tariffs could affect its business.
What to watch
- Execution of BioLife integration and realization of expected operating expense synergies.
- Consumables and services demand trends and capital equipment order-book development.
- Delivery against FY 2026 adjusted revenue guidance of $844M - $852M and adjusted operating margin guidance of 16.0% - 16.3%.
- The impact of the $41,242 Q3 intangible asset impairment charge on GAAP results.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities at September 30, 2026, were $863 million, compared to $768 million at December 31, 2025.
- Cash and cash equivalents were $ 726,960 at September 30, 2026, compared to $ 566,021 at December 31, 2025.
- Marketable securities were 136,019 at September 30, 2026, compared to 201,607 at December 31, 2025.
- Convertible Senior Notes due 2028, net were 555,596 at September 30, 2026, compared to 542,213 at December 31, 2025.
- Nine months ended September 30, 2026 total cash provided by operating activities was 104,160, compared to 91,713.
- Nine months ended September 30, 2026 purchases of property, plant and equipment were (14,992), compared to (15,366).
- Nine months ended September 30, 2026 net increase in cash, cash equivalents and restricted cash was 162,989, compared to net decrease of (8,608).
Analysis
Repligen reported Q3 2026 total revenue of $ 209,314, compared with $ 188,805 in Q3 2025. Reported revenue growth was 11 %, while organic revenue growth was 12 %. Management attributed performance to continued strength across its diversified portfolio, healthy consumables and services trends, and a growing capital equipment order book. Product revenue was $ 209,270, compared with $ 188,766, while royalty and other revenue was 44, compared with 39.
Profitability diverged sharply between GAAP and adjusted measures. Q3 GAAP loss from operations was $ (29,546), versus income from operations of $ 16,825, and GAAP net loss was $ (38,432), versus net income of $ 14,911. The release identifies a $41,242 intangible asset impairment charge as the primary driver of the operating loss. By contrast, adjusted income from operations was $ 33,288, compared with $ 26,770, and adjusted EPS was $ 0.53, compared with $ 0.46. Adjusted operating margin was 15.9 %, compared with 14.2 %, and adjusted EBITDA margin was 20.9 %, compared with 19.0 %.
For the nine months ended September 30, 2026, total revenue was $ 607,697, compared with $ 540,343, with reported revenue growth of 13 % and organic revenue growth of 12 %. GAAP income from operations was $ 370, compared with $ 37,299, while adjusted income from operations was $ 97,196, compared with $ 72,086. Nine-month operating cash flow was 104,160, compared with 91,713. Cash, cash equivalents and marketable securities were $863 million at September 30, 2026, compared with $768 million at December 31, 2025, while Convertible Senior Notes due 2028, net were 555,596.
The Company raised FY 2026 adjusted total reported revenue guidance to $844M - $852M, representing reported growth of 14.5% - 15.5%, and guided organic growth of 12% - 13%. The guide includes BioLife Solutions from its October 6, 2026 closing date. Repligen expects adjusted gross margin of 53.7% - 54.2%, adjusted income from operations of $135M - $139M, adjusted operating margin of 16.0% - 16.3%, adjusted net income of $119M - $122M, and adjusted diluted EPS of $2.05 - $2.09. The release states that inorganic growth, primarily from BioLife net of the Polymem divestiture, provides an approximately 2.5 point tailwind to total reported revenue guidance.
Management, verbatim
We delivered a record third quarter, with $209 million in revenue and 12.5% organic growth, driven by continued strength across our diversified portfolio. End-market demand continues to improve, with healthy trends in consumables and services complemented by a growing capital equipment order book.
Olivier Loeillot, President and Chief Executive Officer of Repligen
The completion of the BioLife acquisition in October marks a significant milestone for Repligen, and integration is progressing well. Early customer feedback has been very encouraging, and we have already taken actions to realize a sizable portion of our expected operating expense synergies. Our strong year-to-date performance, continued order momentum and the addition of BioLife give us confidence to raise our full-year guidance again.
Olivier Loeillot, President and Chief Executive Officer of Repligen
Not in the filing
stated, not guessed- Previous outlook was not provided; comparison of actual results with prior guidance is unavailable.
- No reportable operating segment revenue was provided.
- Free cash flow was not reported.
- Q3 operating cash flow was not reported.
- Capital-return activity, including share repurchases and dividends, was not reported.
- FY 2026 GAAP guidance was not provided.
- FY 2026 operating-expense guidance was not provided.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.